Sulbactam

Background: Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.

Indication: Sulbactam is currently available in combination products with ampicillin. Within this formulation it is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.

Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus.

Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and Enterobacter spp.

Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).

Associated Conditions: Animal bite, Bacterial Infections, Bacterial Infections caused by Beta lactamase producing bacteria, Bacterial Sinusitis, Bites, Human, Catheter Related Infections, Community Acquired Pneumonia (CAP), Gynecological Infection, Infective Endocarditis (IE), Intraabdominal Infections, Nosocomial Pneumonia, Postoperative Infections, Postoperative Wound Infection, Skin and Subcutaneous Tissue Bacterial Infections, Complicated Bacterial Infections caused by Beta lactamase producing bacteria, Moderate Bacterial Infections, Severe Bacterial Infections

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Phase 3

Completed

Conditions: Hospital-acquired Bacterial Pneumonia
Acinetobacter Baumannii-calcoaceticus Complex
Bacteremia
Ventilator-associated Bacterial Pneumonia
Colistin Resistant ABC

Interventions: Drug: Colistin
Drug: Sulbactam
Drug: Durlobactam
Drug: Imipenem/Cilastatin 500 mg/500 mg

Locations: 🇹🇷
Entasis Research Site 2, Ankara, Turkey
🇷🇺
Entasis Research Site 3, Novosibirsk, Russian Federation
🇹🇷
Entasis Research Site, Trabzon, Turkey

Phase 1

Completed

Interventions: Drug: ETX2514
Drug: Placebo
Drug: Sulbactam
Drug: Imipenem/Cilastatin

Phase 4

Completed

Locations: 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand